UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1356-1384

2022

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes

Diabetes care, 2022-05, Vol.45 (5), p.1170-1176

2022

Volltextzugriff (PDF)

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

Scientific reports, 2019-01, Vol.9 (1), p.566-566, Article 566

2019

Volltextzugriff (PDF)

Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.54-62

2019

Volltextzugriff (PDF)

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Targeted oncology, 2017-12, Vol.12 (6), p.709-718

2017

Volltextzugriff (PDF)

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer

Cancer medicine (Malden, MA), 2016-09, Vol.5 (9), p.2567-2578

2016

Volltextzugriff (PDF)

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer

Scientific reports, 2022-05, Vol.12 (1), p.9054-9054, Article 9054

2022

Volltextzugriff (PDF)

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

Frontiers in immunology, 2022-09, Vol.13

2022

Volltextzugriff (PDF)

Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Current treatment options in oncology, 2023-12, Vol.24 (12), p.1802-1814

2023

Volltextzugriff (PDF)

Molecular therapeutic targets in non-small cell lung cancer

Expert review of anticancer therapy, 2020-08, Vol.20 (8), p.647-661

2020

Volltextzugriff (PDF)

A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21062-e21062

2023

Volltextzugriff (PDF)

A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9138-TPS9138

2022

Volltextzugriff (PDF)

Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8536-8536

2018

Volltextzugriff (PDF)

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations

Expert opinion on pharmacotherapy, 2022-09, Vol.23 (14), p.1569-1575

2022

Volltextzugriff (PDF)

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Cancer cell, 2023-02, Vol.41 (2), p.304-322.e7

2023

Volltextzugriff (PDF)

Cyclin-dependent kinase inhibitors for the treatment of lung cancer

Expert opinion on pharmacotherapy, 2020-05, Vol.21 (8), p.941-952

2020

Volltextzugriff (PDF)

The “liquid biopsy” in non-small cell lung cancer—not quite ready for prime time use

Translational cancer research, 2016-10, Vol.5 (S4), p.S632-S635

2016

Volltextzugriff (PDF)

Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

The Annals of pharmacotherapy, 2021-06, Vol.55 (6), p.697-704

2021

Volltextzugriff (PDF)

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)

Journal of clinical oncology, 2024-02, Vol.42 (5), p.562-570

2024

Volltextzugriff (PDF)

Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin

Journal of cancer survivorship, 2015-06, Vol.9 (2), p.252-259

2015

Volltextzugriff (PDF)

Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2024-09, Vol.42 (25), p.3058-3060

2024

Volltextzugriff (PDF)

Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC

Clinical lung cancer, 2019-07, Vol.20 (4), p.e495-e503

2019

Volltextzugriff (PDF)

Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time

Journal of clinical oncology, 2024-08, Vol.42 (23_suppl), p.215-215

2024

Volltextzugriff (PDF)

1 – 25 von 144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(113)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(73)
Humans
(48)
Oncology
(32)
Animals
(22)
Female
(21)
Physical Sciences
(17)
Middle Aged
(13)
Adult
(11)
Aged
(11)
Lung Neoplasms - Pathology
(11)
Male
(11)
Immunotherapy
(10)
Risk Factors
(10)
Science & Technology - Other Topics
(10)
Chemistry
(9)
Immunology
(9)
Lung Neoplasms - Drug Therapy
(9)
Medicin Och Hälsovetenskap
(9)
Mice
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Molecular therapeutic targets in non-small cell lung cancer

524 Tim-4+ resident macrophages impair anti-tumor immunity in the serous body cavities By sequestering viable and cytotoxic CD8+ T cells expressing high levels of phosphatidylserine

A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC)

Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity

A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab

Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Cyclin-dependent kinase inhibitors for the treatment of lung cancer

The “liquid biopsy” in non-small cell lung cancer—not quite ready for prime time use

Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)

Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin

Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC

Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time

Suchergebnisse filtern